Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q2 2014 · 10-Q
Revenue$26.28M$26.28M+26.2% vs Q2 2013 Net Income$9.30M$9.30M+57.8% vs Q2 2013 EPS Diluted$0.60$0.60+50.0% vs Q2 2013 Gross Profit$15,934,000+15.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$6,722,442+88.6% Free Cash Flowderived$6,321,597+81.1% Margins · derivedGross margin60.6%−5.4 pt vs Q2 2013
Operating margin57.9%+12.7 pt vs Q2 2013
Net margin35.4%+7.1 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 4, 2014 · 35 d after period end